How Medtech Trends 2026 Are Set to Reshape Eurasia’s Healthcare Investment Landscape

Subheadline: Pricing pressures, supply chain realignment, and new technology platforms are creating both challenges and opportunities for healthcare systems and investors across Eurasia.

The global medtech industry is entering a period of accelerated transformation. While much of the attention focuses on North America and Western Europe, the ripple effects are being felt across the broader Eurasian region—from the European Union’s eastern members to Türkiye, the Caucasus, and Central Asia. As pricing reforms, procedure shifts, and digital innovations redefine competitive dynamics, healthcare suppliers, distributors, and national systems in Eurasia must recalibrate their strategies.

This analysis draws on five defining trends identified in the 5 Medtech Trends to Watch in 2026 report by Clarivate, examining how each trend intersects with the regional business environment.

The China VBP Ripple Effect Reaches Eurasian Markets

Mainland China’s expanded volume-based procurement (VBP) is no longer a localized policy exercise. The program’s sophisticated anchoring logic, deep price compression, and preference for domestic manufacturers are creating a new global benchmark for device pricing. For medtech companies active in Eurasia, the consequences are twofold. First, lower price expectations in China increasingly influence procurement negotiations across emerging markets, including Central Asia and the Caucasus. Second, multinational manufacturers are rebalancing their global portfolios, diverting volume toward higher-margin regions, which could affect supply availability in smaller markets.

For Eurasian governments seeking to expand healthcare access, China’s VBP offers a model for cost containment. However, adopting similar mechanisms without a robust domestic innovation base could leave regional systems dependent on imported low-cost devices. Policymakers in the EU’s newer member states may also face pressure to align their public procurement frameworks with the pricing levels now common in major Asian economies.

Outpatient Procedure Migration Reshapes Service Delivery

Across the United States, the expansion of ambulatory surgery center (ASC) eligibility is accelerating a long-term global trend toward outpatient care. While this shift is most visible in U.S. regulations, similar dynamics are evident in Europe and parts of Eurasia, where day-surgery models are expanding to reduce hospital burdens. Türkiye, for example, has seen private hospital chains invest heavily in outpatient infrastructure, while Kazakhstan and Poland are modernizing their secondary care networks.

For medtech manufacturers, the move to lower-cost outpatient settings changes product design priorities. Devices must be simpler, less invasive, and suitable for shorter recovery times. This, in turn, influences how companies market their portfolios across Eurasian health systems. Suppliers that develop specific surgical tools and support services for outpatient centers could gain early mover advantages in regions where healthcare modernization is accelerating.

The strategic implication for investors is clear: companies with strong outpatient-oriented product lines are better positioned to capture demand from the shift away from traditional hospital-based care. Regional distributors and logistics providers serving these settings also stand to benefit, provided they can adapt to more complex service requirements.

Supply Chain Pressures and the Search for Regional Resilience

Global trade disruptions and tariff tensions have exposed the vulnerabilities of concentrated medical device production. In response, manufacturers are diversifying sourcing and pursuing multi-region manufacturing footprints. This recalibration is particularly relevant for Eurasia, which is seeking to position itself as both a logistical bridge and a manufacturing alternative. The Middle Corridor, which links Turkey, the Caucasus, and Central Asia to China, could become a viable transit route for medical devices and components.

European Union members with mature healthcare industries, such as Germany and Italy, may see some production reshored to Eastern Europe, where labor costs are lower but infrastructure and technical capacity are still developing. Countries like Poland, Hungary, and Serbia are already hospitable to foreign medical device assembly, but the new emphasis on resilience could accelerate investments in higher-tech production tiers.

For companies operating in Central Asia, maintaining multiple suppliers is more challenging due to logistics complexities. Yet the region's growing healthcare demand—driven by population growth and aging—creates an opportunity to develop local production partnerships, especially for basic consumables and disposables. Governments can facilitate this by offering incentives aligned with public health priorities.

GLP-1 Therapies: A Health-Economic Disruptor

The rapid uptake of GLP-1 receptor agonists is altering clinical pathways across developed and emerging health systems. While initial impacts on bariatric surgery volumes are visible in wealthy markets, longer-term effects on diabetes management, cardiovascular monitoring, and obesity-related comorbidity care are still unfolding. In Eurasia, rates of obesity and type 2 diabetes vary widely, but the trend toward GLP-1 use will inevitably shape future interventions.

European health systems are among the earliest adopters of GLP-1 therapies, though budget pressures may lead to strict eligibility criteria. In Türkiye and Central Asia, access is limited by cost and reimbursement gaps. However, if generic or biosimilar-based formulations become available in the next three to five years, demand could rise sharply. Medtech firms should prepare for indirect effects: as GLP-1 use expands, obesity-related surgical and monitoring device markets will see slower growth or reduced rates of new procedures, while cardiovascular and metabolic diagnostics could experience increased use.

The strategic takeaway for regional healthcare planners is to consider these biological therapies as part of integrated care pathways, not just pharmaceutical line items. Investments in patient education, early assessment, and digital tracking could complement drug therapy and reduce long-term costs. For capital allocators, opportunities may lie in companies that provide supportive technologies for metabolic health, rather than those focused solely on bariatric interventions.

Platform-Based Competition and the Regional Digital Leap

Enabling technologies such as robotics, imaging, navigation, and digital workflow software are transforming medtech into an ecosystem competition. Rather than isolated products, devices increasingly function as parts of connected platforms that span surgical planning, execution, and post-operative care. This trend is highly relevant for Eurasia, where digital infrastructure and talent pools are developing unevenly.

Within the EU, advanced surgical robotics and intraoperative intelligence are already part of premier medical centers. In Eastern Europe and Central Asia, however, adoption remains slower due to budget limitations and infrastructure gaps. This creates a significant potential for leapfrogging. Cloud-based platforms and digital twins could allow secondary care hospitals to access advanced guidance without purchasing costly hardware. Local technology startups in Kazakhstan, Georgia, and Poland are emerging in health-tech innovation, and integrating them with global platforms could accelerate regional modernization.

Platform-based competition also affects business models. Companies that control the highest-value data and workflow ecosystems gain persistent customer relationships. For Eurasian distributors and system integrators, partnering with leading technology providers rather than only selling hardware may offer a path to higher margins and long-term relevance.

Future Outlook: 3–5 Years

Over the next five years, Eurasia’s medtech landscape will likely become more differentiated. The EU will remain the regulatory and market anchor, but growth dynamics will shift toward lower-income membership states and non-EU countries that are investing in healthcare infrastructure. The pricing pressure radiating from China will force manufacturers to seek new revenue pools; the expansion of outpatient care will create demand for procedure-specific solutions; and supply chain adjustments will lead to more distributed manufacturing, with strengthening ties to Turkey, Poland, and potentially Armenia and Georgia as emerging sites.

The GLP-1 disruption will mature, and its long-term impact on surgical volumes may stabilize as bariatric procedures are reserved for more complex cases. In parallel, platform technologies will become more accessible, particularly in semi-urban and rural regions that previously lacked specialized care. Companies that integrate telemedicine, remote monitoring, and local support networks will fill the gap.

For investors and business strategists, the key to success will be agility. They must monitor and anticipate pricing policies across all healthcare systems, invest in modular and scalable product lines, build regional supply chains that can withstand trade shocks, and forge alliances with digital innovators. Eurasia’s diversity means that tailored approaches are essential; a one-size-fits-all strategy will fail in a region where available infrastructure, regulatory regimes, and purchasing power vary vastly.

Key Takeaways

• Mainland China's volume-based procurement model will influence pricing expectations and procurement policies in many Eurasian markets, potentially expanding access but also challenging foreign manufacturers.
• The shift to outpatient and ambulatory care creates opportunities for companies that adapt product designs and commercial models to lower-cost, higher-volume settings.
• Supply chain reconfiguration across Eurasia will reward manufacturers that diversify production geographically and develop trade corridor resilience.
• GLP-1 therapies will alter the demand for surgical devices and associated monitoring equipment, with implications for regional health budgeting and clinical planning.
• Platform-based competition, combining hardware and software ecosystems, offers a path for Eurasian health systems to leapfrog traditional infrastructure limits.

Sources

Clarivate, 5 Medtech Trends to Watch in 2026: https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026